Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-Analysis
Authors:
Open Access
- 1 November 2020
- journal article
- review article
- Published by SAGE Publications in American Journal of Men's Health
- Vol. 14 (6)
Abstract
We report safety and efficacy of a combination therapy, comprising tamsulosin and phosphodiesterase type 5 inhibitors (PDE5-Is), relative to monotherapy, to ascertain its potential in treating lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) secondary to benign prostatic hyperplasia (BPH) after 3 months’ treatment. We screened MEDLINE, EMBASE, and the Cochrane Controlled Trials Register databases, for randomized controlled trials, and obtained eight articles comprising 1144 participants. Results showed that the combination group had superior outcomes with regard to International Prostate Symptom Score (IPSS) and Qmax, compared to the other two groups. The combination group also had superior efficacy with regard to International Index of Erectile Function (IIEF) than the tamsulosin group, but not over the PDE5-Is group. Further, the combination group showed better efficacy in IPSS voiding and quality of life (QoL) compared to the PDE5-Is group. An analysis of safety outcomes revealed extremely high adverse events (AEs) and pain in the combination group. However, therapy discontinuation due to pain and AEs did not increase with increase in AEs. Overall, our findings indicate that a combination of tamsulosin and PDE5-Is is superior to individual tamsulosin and PDE5-Is monotherapy, with regard to improving LUTS and ED secondary to BPH.Keywords
Funding Information
- National Nature Science Foundation of China (81870525, 81801429)
This publication has 38 references indexed in Scilit:
- Tadalafil Enhances the Inhibitory Effects of Tamsulosin on Neurogenic Contractions of Human Prostate and Bladder NeckThe Journal of Sexual Medicine, 2012
- Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic reviewBJU International, 2010
- Lower urinary tract symptoms and sexual dysfunction: a common approachBJU International, 2008
- Is the Current Practice Providing an Integrated Approach to the Management of LUTS and ED in Primary Care? An Audit and Literature ReviewThe Journal of Sexual Medicine, 2007
- Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiologyBJU International, 2006
- Assessment of sexual dysfunction in patients with benign prostatic hyperplasiaBJU International, 2006
- Lower Urinary Tract Symptoms in Patients with Erectile Dysfunction: Analysis of Risk FactorsThe Journal of Sexual Medicine, 2006
- Cardiovascular Effects of the 3 Phosphodiesterase-5 Inhibitors Approved for the Treatment of Erectile DysfunctionCirculation, 2004
- Summary of the Recommendations on Sexual Dysfunctions in MenThe Journal of Sexual Medicine, 2004
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996